Bisphosphonates and RSD

Bisphosphonates and RSD – updated
January 1, 2012 at 11:04pm

12/21/2013 note update – In light of the recent double blind study done by USCSD I decided to repost this and see if any of you with RSD have tried this type of infusion treatment and if so, what did you think? –

I have questions:

  • The study said patients with “82 patients with CRPS-I at either hand or foot” were tested… does that mean it was not tried on full body patients, like myself and/or type 2 (nerve injury patients)?
  • Will it also help in cases where there is a nerve injury/type 2?
  • How long had the patients in the study had CRPS?
  • Can people who have kidney problems such as chronic kidney stones use this treatment?
  • Zometa is in the same Bisphosphonate class as Neridronate
  • The FDA says “Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of Zometa should not exceed 4 mg and the duration of infusion should be no less than 15 minutes [see Warnings And Precautions (5.2)]. In the trials and in post marketing experience, renal deterioration, progression to renal failure and dialysis, have occurred in patients, including those treated with the approved dose of 4 mg infused over 15 minutes. There have been instances of this occurring after the initial Zometa dose.”
  • It also said that women can get birth defects from it on unborn babies and not to use it on children, and it may or may not be transmitted through breast milk. So, does the patient need to not want to have children, or be done having children when it is administered?
  • It doesn’t mention that there were any side effects in the 82 patients who got it? Do you know what if any other side effects there could be?
    1 year no symptoms is amazing, but is that a ‘cure’ or ‘remission’. Could the auto-antigens just be tricked into ‘being good’ as they are w/ the ketamine infusions and have symptoms return on future injuries/traumas?

Original note posted on Jan. 2, 2012: At the hospital recently my internist doctor was talking about Bisphosphonates (also called diphosphonates) and using them in the treatment of RSD. Bisphosphonates are a class of drugs that prevent the loss of bone mass, used to treat osteoporosis and similar diseases. They are called bisphosphonates because they have two phosphonate (PO3) groups and are similar in structure to pyrophosphate. With RSD you can have bone loss. According to Wikipedia; Evidence shows that they reduce the risk of osteoporotic fracture in those who have had previous fractures. However, they do not reduce fracture risk in those with osteoporosis who have not previously had a fracture. Apparently, Bone undergoes constant turnover and is kept in balance (homeostasis) by osteoblasts creating bone and osteoclasts destroying bone. Bisphosphonates inhibit the digestion of bone by encouraging osteoclasts to undergo apoptosis, or cell death, thereby slowing bone loss. The uses of bisphosphonates include the prevention and treatment of osteoporosis, osteitis deformans (“Paget’s disease of bone”), bone metastasis (with or without hypercalcaemia), multiple myeloma, primary hyperparathyroidism, osteogenesis imperfecta, and other conditions that feature bone fragility. You can read more about it at Let me know what you think about this and if you have tried it.

One thought on “Bisphosphonates and RSD

  1. Jodi L. Orvis-Dragon

    Thank you for writing about Bisphosphonates and RSD. Your input will help those searching for treatments! We are excited to buy a copy of your new book “From Wheels to Heals”! Your book have positively changed my life and the lives of thousands around the world. I also enjoyed reading your blog and seeing the faith you have to move mountains. Recently I have been able to put my trust in God and know that he cares. Sometimes we can get lost when we are in constant pain. I appreciate your friendship and support. Thank you for caring and for making a difference.

Leave a Reply

Your email address will not be published. Required fields are marked *